Activating BRAF mutations have also been documented in a variety of human cancers other than melanoma, such as ∼10% in colorectal cancer (CRC), approximately 50% in thyroid cancer [7], and several percent in NSCLC [11]. This evidence concerns the gene BRAF and colorectal carcinoma.